Public funding for medical research in relation to the burden of disease caused by cardiovascular diseases and neoplasms in Germany

  • Manuel Krone
  • Vera Dufner
  • Martin Wagner
  • Götz Gelbrich
  • Georg Ertl
  • Peter U. Heuschmann
Original Paper
  • 30 Downloads

Abstract

Background

Public funding for medical research in Germany is primarily provided by the German Research Foundation (DFG) and the Federal Ministry of Education and Research (BMBF). The aim of this study was to analyze the amount of national public funding for medical research on predominant causes of death in Germany, cardiovascular diseases and neoplasms, in relation to the burden of these diseases in Germany.

Methods

Three evaluators categorized medical research projects funded by the DFG or BMBF between 2010 and 2012 into the categories “Diseases of the circulatory system” (with subgroups “Ischemic heart diseases”, “Heart failure” and “Cerebrovascular diseases”) and “Neoplasms”. The total amount of public funding by the national agencies was analyzed in relation to the burden of disease for the respective disease condition.

Results

Information on national public funding for medical research of 2091 million euros was available; of those, 246.8 million euros (11.8%) were categorized being spent for research on “Neoplasms”, 118.4 million euros (5.7%) for research on “Diseases of the circulatory system”. This results in 362.08 euros per case of death, 16.58 euros per year of life lost (YLL) and 16.04 euros per disability-adjusted life year (DALY) for “Neoplasms” and in 113.44 euros per case of death, 8.05 euros per YLL and 7.17 euros per DALY for “Diseases of the circulatory system”.

Conclusions

In Germany, research on cardiovascular diseases receives a lower share of national public funding for medical research compared to oncological research. These results are comparable to other European countries.

Keywords

Public research funding Cardiovascular research Burden of disease 

Notes

Acknowledgements

The results are part of the MD thesis of Manuel Krone.

Compliance with ethical standards

Conflict of interest

MK, VD and MW declare no conflict of interest. GG reports grants from University Göttingen within DZHK analysis projects (the DZHK is funded by a BMBF Grant), personal fees from Charité-Universitätsmedizin Berlin within the TIM-HF-II trial for data safety and monitoring board membership (TIM-HF-II is supported by a BMBF Grant to the Charité), grants from University Hospital Würzburg within the MOOD-HF trial for biometry and steering committee membership (MOOD-HF is supported by a BMBF grant and an unrestricted grant to the University Hospital Würzburg from Lundbeck), grants from Reha-Klinikum Roter Hügel Bayreuth within the CaRitaS-trial for biometry and steering committee membership, grants from University Göttingen within the FIND-AF-randomized trial (FIND-AF-randomized is supported by an unrestricted grant to the University Göttingen from Boehringer-Ingelheim), outside the submitted work. GE reports research grants from the German Ministry of Education and Research (BMBF), counselling contract with Vifor Pharma, Lundbeck non-financial support, Bayer Grants, Novartis Grants and personal fees, outside the submitted work. PUH reports research grants from German Ministry of Research and Education, European Union, Charité-Universitätsmedizin Berlin, Berlin Chamber of Physicians, German Parkinson Society, German Heart Foundation, University Hospital Würzburg, Robert Koch Institute, Charité-Universitätsmedizin Berlin (within Mondafis; supported by an unrestricted research grant to the Charité from Bayer), University Göttingen (within FIND-AF randomized; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), outside the submitted work.

References

  1. 1.
    Statistisches Bundesamt (2013) Todesursachen in Deutschland 2012. https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Todesursachen/Todesursachen2120400127004.pdf?_blob=publicationFile. Accessed 26 September 2015
  2. 2.
    Hanna M (2015) Matching taxpayer funding to population health needs. Circ Res 116(8):1296–1300.  https://doi.org/10.1161/CIRCRESAHA.114.305585 CrossRefPubMedGoogle Scholar
  3. 3.
    Aoun S, Pennebaker D, Pascal R (2004) To what extent is health and medical research funding associated with the burden of disease in Australia? Aust N Z J Public Health 28(1):80–86.  https://doi.org/10.1111/j.1467-842X.2004.tb00637.x CrossRefPubMedGoogle Scholar
  4. 4.
    Lamarre-Cliche M, Castilloux AM, LeLorier J (2001) Association between the burden of disease and research funding by the Medical Research Council of Canada and the National Institutes of Health. A cross-sectional study. Clin Invest Med 24(2):83–89PubMedGoogle Scholar
  5. 5.
    Xu G, Zhang Z, Lv Q, Li Y, Ye R, Xiong Y, Jiang Y, Liu X (2014) NSFC health research funding and burden of disease in China. PLoS One 9(11):e111458.  https://doi.org/10.1371/journal.pone.0111458 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Martinez-Martinez E, Zaragoza ML, Solano E, Figueroa B, Zuniga P, Laclette JP (2012) Health research funding in Mexico: the need for a long-term agenda. PLoS One 7(12):e51195.  https://doi.org/10.1371/journal.pone.0051195 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kinge JM, Roxrud I, Vollset SE, Skirbekk V, Røttingen JA (2014) Are the Norwegian health research investments in line with the disease burden? Health Res Policy Syst 12:64.  https://doi.org/10.1186/1478-4505-12-64 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Catala Lopez F, Alvarez Martin E, Genova Maleras R, Morant Ginestar C (2009) Relacion en Espana entre la investigacion sanitaria financiada por el Sistema Nacional de Salud y la carga de enfermedad en la comunidad [Relationship between research funding in the Spanish National Health System and the burden of disease]. Rev Esp Salud Publ 83(1):137–151CrossRefGoogle Scholar
  9. 9.
    Luengo-Fernandez R, Leal J, Gray AM (2012) UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden? Eur J Neurol 19(1):149–154.  https://doi.org/10.1111/j.1468-1331.2011.03500.x CrossRefPubMedGoogle Scholar
  10. 10.
    Luengo-Fernandez R, Leal J, Gray A (2015) UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. BMJ Open 5(4):e006648.  https://doi.org/10.1136/bmjopen-2014-006648 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gross CP, Anderson GF, Powe NR (1999) The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 340(24):1881–1887.  https://doi.org/10.1056/NEJM199906173402406 CrossRefPubMedGoogle Scholar
  12. 12.
    Gillum LA, Gouveia C, Dorsey ER, Pletcher M, Mathers CD, McCulloch CE, Johnston SC (2011) NIH disease funding levels and burden of disease. PLoS One 6(2):e16837.  https://doi.org/10.1371/journal.pone.0016837 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Deutsche Forschungsgemeinschaft (2012) Förderatlas 2012. WILEY-VCH, WeinheimGoogle Scholar
  14. 14.
    Loos S, Albrecht M, Sander M, Schliwen A (2014) Forschung und Innovation in der Universitätsmedizin. Studien zum deutschen Innovationssystem 7. https://www.e-fi.de/fileadmin/Innovationsstudien_2014/StuDIS_7_2014.pdf. Accessed 11 November 2017
  15. 15.
    Die Bundesregierung (2013) Förderkatalog. http://foerderportal.bund.de/foekat/. Accessed 7 October 2013
  16. 16.
    Deutsche Forschungsgemeinschaft (2011) Jahresbericht 2010—Programme und Projekte. http://jahresbericht.dfg.de/2010/ (As of 28 July 2011)
  17. 17.
    Deutsche Forschungsgemeinschaft (2012) Jahresbericht 2011—Programme und Projekte. http://jahresbericht.dfg.de/2011/ (As of 5 July 2012)
  18. 18.
    Deutsche Forschungsgemeinschaft (2013) Jahresbericht 2012 - Programme und Projekte. http://jahresbericht.dfg.de/2012/ (As of 4 July 2013)
  19. 19.
    Deutsches Institut für Medizinische Dokumentation und Information (2014) Todesursachen in der Todesbescheinigung. https://www.dimdi.de/static/de/klassi/icd-10-who/mortalitaet/totenscheinanleitung.pdf. Accessed 26 September 2015
  20. 20.
    Gesundheitsberichterstattung des Bundes (2014) Sterbefälle, Sterbeziffern (je 100.000 Einwohner, altersstandardisiert) (ab 1998). http://www.gbe-bund.de (As of 26 November 2014)
  21. 21.
    World Health Organization (2014) Global Health Estimates 2014 Summary Tables, DALY estimates, WHO Member States, 2012. http://www.who.int/entity/healthinfo/global_burden_disease/GHE_DALY_2012_country.xls. Accessed 14 November 2015
  22. 22.
    World Health Organization (2014) Global Health Estimates 2014 Summary Tables, YLL estimates, WHO Member States, 2012. http://www.who.int/entity/healthinfo/global_burden_disease/GHE_YLL_2012_country.xls. Accessed 14 November 2015
  23. 23.
    Murray CJ, Vos T, Lozano R et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2197–2223.  https://doi.org/10.1016/S0140-6736(12)61689-4 CrossRefPubMedGoogle Scholar
  24. 24.
    World Health Organization (2013) WHO methods and data sources for global burden of disease estimates 2000–2012. http://www.who.int/entity/healthinfo/statistics/GlobalDALYmethods_2000_2011.pdf. Accessed 15 November 2015
  25. 25.
    Die Bundesregierung (2015) Förderkennzeichen 01EO1004. http://foerderportal.bund.de/foekat/jsp/SucheAction.do?actionMode=view&fkz=01EO1004. Accessed 27 November 2015
  26. 26.
    Die Bundesregierung (2016) Förderkennzeichen 01EO0801. http://foerderportal.bund.de/foekat/jsp/SucheAction.do?actionMode=view&fkz=01EO0801. Accessed 21 September 2016
  27. 27.
    Hegde D, Sampat BN (2014) Can private money buy public science? Disease Group Lobbying and Federal Funding for Biomedical Research (July 16, 2014). Forthcoming in Management Science. http://ssrn.com/abstract=1962937. Accessed 23 November 2015
  28. 28.
    Groneberg-Kloft B, Scutaru C, Fischer A, Welte T, Kreiter C, Quarcoo D (2009) Analysis of research output parameters: density equalizing mapping and citation trend analysis. BMC Health Serv Res 9:16.  https://doi.org/10.1186/1472-6963-9-16 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Deutsche Forschungsgemeinschaft (2016) Jahresbericht 2016, Aufgaben und Ergebnisse. http://www.dfg.de/download/pdf/dfg_im_profil/geschaeftsstelle/publikationen/dfg_jb2016.pdf. Accessed 19 March 2018
  30. 30.
    Lauer MS, Gordon D, Olive M (2015) Matching taxpayer funding to population health needs: not so simple. Circ Res 116(8):1301–1303.  https://doi.org/10.1161/CIRCRESAHA.114.305893 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Heusch G, Eschenhagen T, Dimmeler S (2017) Cardiovascular Research in Germany. Circ Res 121(5):492–495.  https://doi.org/10.1161/CIRCRESAHA.117.311132 CrossRefPubMedGoogle Scholar
  32. 32.
    Deutsche Herzstiftung e.V (2013) Deutscher Herzbericht. Frankfurt am MainGoogle Scholar
  33. 33.
    Modelmog D, Goertchen R (1992) Accuracy of death certificates: a population-based, complete-coverage, one-year autopsy study in East Germany. Cancer Causes Control 3(6):541–546CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Clinical Epidemiology and BiometryUniversity of WürzburgWürzburgGermany
  2. 2.Clinical Trial CenterUniversity Hospital WürzburgWürzburgGermany
  3. 3.Department of Internal Medicine IUniversity Hospital WürzburgWürzburgGermany
  4. 4.Comprehensive Heart Failure CenterWürzburgGermany
  5. 5.Institute for Hygiene and MicrobiologyUniversity of WürzburgWürzburgGermany

Personalised recommendations